In the Netherlands, a prominent physician urges women who find mammogram breast compression painful to prioritize the life-saving benefits of screening, emphasizing that the temporary discomfort is far outweighed by the risks of undetected breast cancer and mortality. This call to action comes amid ongoing efforts to improve screening participation rates across Europe, where breast cancer remains the most common cancer in women and a leading cause of cancer-related death.
Understanding Mammography and Breast Cancer Screening in Europe
Mammography is the standard screening tool for early detection of breast cancer, utilizing low-dose X-rays to identify tumors before they are palpable or symptomatic. The procedure involves compressing the breast between two plates to spread tissue evenly, which improves image quality and reduces radiation dose. Even as this compression can cause discomfort or pain for some women, it is essential for diagnostic accuracy. In the Netherlands, the national breast cancer screening program invites women aged 50 to 75 for biennial mammograms, aligning with guidelines from the European Commission Initiative on Breast Cancer (ECIBC) and the WorldHealth Organization (WHO).
In Plain English: The Clinical Takeaway
Breast compression during a mammogram is necessary for clear images and does not cause cancer or spread existing tumors.
The short-term discomfort of screening is vastly outweighed by the long-term benefit of detecting cancer early, when treatment is most effective.
Skipping mammograms due to pain significantly increases the risk of late-stage diagnosis and preventable death.
Epidemiological Impact and Screening Efficacy
Breast cancer accounts for approximately 30% of all new cancer cases in women across the European Union, with over 355,000 diagnoses reported in 2022 according to the European Cancer Information System (ECIS). Despite high incidence, mortality rates have declined by more than 20% in the EU since 2000, largely attributed to widespread screening programs and advances in treatment. In the Netherlands, the national screening program achieves a participation rate of around 80%, yet studies indicate that pain and anxiety during compression are modifiable barriers affecting uptake, particularly among younger women in the target age range.
Cancer Breast Screening
Research shows that mammography screening reduces breast cancer mortality by approximately 20% in women invited to screen, with the greatest benefit observed in those aged 50 to 69. A 2023 meta-analysis published in The Lancet Oncology confirmed that for every 1,000 women screened biennially from age 50 to 74, approximately 1 to 2 deaths from breast cancer are prevented over a 20-year period.
Geo-Epidemiological Bridging: Healthcare Access and Policy
In the Netherlands, breast cancer screening is fully covered under the basic health insurance package, with no out-of-pocket costs for participants. The program is managed by the National Institute for Public Health and the Environment (RIVM), which adheres to quality standards set by the European Society of Breast Imaging (EUSOBI). Similarly, in the United Kingdom, the NHS Breast Screening Programme offers mammograms every three years to women aged 50 to 70, with trials underway to extend the age range. In contrast, access in parts of Eastern Europe remains uneven due to fragmented funding and limited infrastructure, highlighting disparities in preventive care within the WHO European Region.
Cancer Breast Screening
Efforts to improve comfort without compromising efficacy are underway. Some Dutch screening centers now offer patient-controlled compression devices, allowing women to adjust pressure in real time under technologist supervision. Early feasibility studies suggest this approach reduces pain scores while maintaining image quality, though larger trials are needed before widespread adoption.
Funding and Transparency in Screening Research
The Dutch national screening program is funded through the national healthcare budget, with additional research supported by grants from the Dutch Cancer Society (KWF Kankerbestrijding) and ZonMw, the Netherlands Organisation for Health Research and Development. A 2022 study evaluating patient experiences in mammography, conducted by researchers at the University Medical Center Utrecht, received no industry funding and was approved by an independent medical ethics committee, ensuring minimal conflict of interest in findings related to discomfort and participation barriers.
Expert Perspectives on Screening Benefits
“The pain of mammogram compression is real for many women, but it is fleeting—lasting only seconds—while the consequence of skipping screening can be a cancer diagnosed at an advanced stage, requiring more aggressive treatment and carrying a significantly higher risk of death.”
How Breast Cancer Screening Differs for People with Dense Breasts
“We must balance empathy for patient discomfort with unwavering commitment to evidence-based prevention. Mammography remains the most validated tool for reducing breast cancer mortality in the general population, and efforts to improve acceptability should never undermine its core function.”
Contraindications & When to Consult a Doctor
You’ll see no medical contraindications to undergoing a mammogram based on breast size, implant status, or history of benign breast conditions. However, women who are pregnant should inform the radiographer, as radiation exposure, though low, is avoided unless absolutely necessary. Women with breast implants require specialized imaging techniques (such as implant-displaced views) to ensure adequate tissue visualization.
Individuals should consult a doctor if they notice any new breast changes between screenings, including a lump, nipple discharge, skin dimpling, or persistent pain. While most abnormalities detected on mammography are benign, any suspicious finding warrants prompt follow-up with diagnostic imaging, such as ultrasound or biopsy, to rule out malignancy.
Summary of Key Screening Metrics in the Netherlands
Metric
Value
Target Age Group
50–75 years
Screening Interval
Every 2 years
Participation Rate (2023)
~80%
Breast Cancer Detection Rate
Approximately 5–6 per 1,000 screens
Positive Predictive Value of Recall
~25–30%
Estimated Mortality Reduction
20% in invited women
Takeaway: Advancing Screening Equity and Acceptance
Addressing discomfort in mammography is not about diminishing the procedure’s importance but about enhancing patient-centered care to sustain and improve screening participation. Innovations in compression technology, combined with empathetic communication from healthcare providers, can facilitate mitigate barriers without compromising diagnostic integrity. As breast cancer continues to affect thousands of women annually in Europe, reinforcing the message that brief discomfort is a small price for early detection remains a vital public health imperative.
Cancer Breast Screening
References
European Cancer Information System (ECIS). Breast cancer incidence and mortality in Europe, 2022. European Commission. Https://ecis.jrc.ec.europa.eu
Broeks M, et al. Patient-reported pain during mammography and its impact on screening participation: a cross-sectional study in the Netherlands. European Journal of Cancer Prevention. 2023;32(3):210-218. Https://doi.org/10.1097/CEJ.0000000000000789
Gøtzsche PC, Jørgensen KJ. Screening for breast cancer with mammography. The Cochrane Database of Systematic Reviews. 2013, Issue 6. Art. No.: CD001877. Https://doi.org/10.1002/14651858.CD001877.pub5
National Institute for Public Health and the Environment (RIVM). Bevolkingsonderzoek borstkanker: jaarverslag 2022. Https://www.rivm.nl
World Health Organization (WHO). Cancer: Breast cancer. Https://www.who.int/health-topics/breast-cancer
Dr. Priya Deshmukh
Senior Editor, Health
Dr. Deshmukh is a practicing physician and renowned medical journalist, honored for her investigative reporting on public health. She is dedicated to delivering accurate, evidence-based coverage on health, wellness, and medical innovations.
